Yoshio Kusakabe, Kazuya Matsumoto, Takahiro Tsuyuki, Yasuhiro Hayashi, Hideaki Watanabe. Baicalin target protein, Annexin A2, is a target of new antitumor drugs. Scientific reports. 2024. 14. 1. 21814-21814
Natsumi Hama, Shigeki Aoki, Chun-Bing Chen, Akito Hasegawa, Youichi Ogawa, Marc Vocanson, Hideo Asada, Chia-Yu Chu, Cheng-Che E Lan, Roni P Dodiuk-Gad, et al. Recent progress of Stevens-Johnson syndrome/toxic epidermal necrolysis: Diagnosis criteria, pathogenesis and therapy. The British journal of dermatology. 2024
Miho Kojima, Hiroki Mieno, Mayumi Ueta, Mitsuko Nakata, Satoshi Teramukai, Yuma Sunaga, Hirotaka Ochiai, Masafumi Iijima, Akatsuki Kokaze, Hideaki Watanabe, et al. Improvement of the Ocular Prognosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A National Survey in Japan. American journal of ophthalmology. 2024. 267. 50-60
Koya Fukunaga, Eri Tsukagoshi, Ryosuke Nakamura, Kayoko Matsunaga, Takeshi Ozeki, Hideaki Watanabe, Akito Hasegawa, Natsumi Hama, Maiko Kurata, Yoshiko Mizukawa, et al. Association of HLA-A∗11:01, HLA-B∗39:01, and HLA-B∗56:03 with salazosulfapyridine-induced cutaneous adverse drug reactions. The journal of allergy and clinical immunology. In practice. 2024. 12. 5. 1355-1358
Koya Fukunaga, Eri Tsukagoshi, Maiko Kurata, Yoshiko Mizukawa, Hiroyuki Niihara, Eishin Morita, Yuko Watanabe, Yukie Yamaguchi, Hideaki Watanabe, Saeko Nakajima, et al. Differential Effects of HLA-B∗15:11 and HLA-A∗31:01 on Carbamazepine-Induced Cutaneous Adverse Reactions. The Journal of investigative dermatology. 2024. 144. 4. 908-911